- Tytuł:
- Połączenie atorwastatyny i ezetymibu w terapii hipercholesterolemii
- Autorzy:
- Pęksa, Jan
- Powiązania:
- https://bibliotekanauki.pl/articles/2080187.pdf
- Data publikacji:
- 2022-06-22
- Wydawca:
- Wydawnictwo Naukowe Medyk sp. z o.o.
- Tematy:
-
atorvastatin
ezetimibe
cardiovascular risk
chronic coronary syndromes
atorwastatyna
ezetymib
ryzyko sercowo-naczyniowe
przewlekłe zespoły wieńcowe - Opis:
- Cardiovascular (CV) diseases are still the leading cause of death in Poland. In treatment of hypercholesterolemia, HMG-CoA reductase inhibitors (statins) are the first-line drugs with proven beneficial effect on patient prognosis. These drugs include one of the two potent statins, atorvastatin. If the target level of LDL cholesterol is not achieved despite lifestyle changes and statin therapy, a drug with a different mechanism of action, e.g. ezetimibe, is added to the treatment. In this way a greater hypolipemic effect is achieved. Single pill combinations (SPC) containing two active substances in one tablet are a good choice. Indications for therapy with SPC preparations with statins and ezetimibe include therapy for primary hypercholesterolemia, mixed hyperlipidemia, heterozygous and homozygous familial hypercholesterolemia, and prevention of CV events in patients at increased risk for these incidents. SPC drug is used to control hypercholesterolemia with atorvastatin and ezetimibe as separate formulations, at the same doses as in the combination formulation. SPC formulations containing 10 mg of ezetimibe in combination with 10 or, 20, or 40 or 80 mg of atorvastatin are available on the Polish pharmaceutical market.
- Źródło:
-
Gabinet Prywatny; 2022, 282, 03; 5-13
2353-8600 - Pojawia się w:
- Gabinet Prywatny
- Dostawca treści:
- Biblioteka Nauki
Artykuł